



## **Ventripoint VMS+3.0 Whole-Heart Analysis System Receives License for Clinical Use from Health Canada**

**Toronto, Ontario, June 25, 2019** – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received a license from Health Canada to market the VMS+3.0 cardiac system for all patients where the Left Ventricle (LV), Right Ventricle (RV), Left Atrium (LA), and Right Atrium (RA) volumes and ejection fractions are warranted or desired.

"We are excited to be able to begin offering the VMS+3.0 system to Canadian hospitals and imaging centres to facilitate the delivery of exceptional patient care nationwide. Our sales team will be meeting with cardiac centres across Canada to showcase how the VMS+3.0 can transform clinical outcomes for patients with heart disease," commented Desmond Hirson, Ventripoint President.

Built around the needs of the patient and the clinician, the VMS+ 3.0 system is a non-invasive diagnostic tool for measuring whole heart function utilizing 2D ultrasound with accuracy comparable to the gold-standard MRI. With heart disease as the leading cause of death for both men and women worldwide, having a cost-effective system to obtain volumetric measurements and ejection fractions for all 4 chambers of the heart is essential for patient management. The new compact and portable system can be set up within minutes providing a streamlined approach within the clinical echo environment where patient case load is continually increasing.

The VMS+ 3.0 system is commercially available in Canada and for investigational use in other jurisdictions.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937  
Email: [gadams@ventripoint.com](mailto:gadams@ventripoint.com)

### **Forward Looking Statements:**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release**